J Mov Disord.
2019 Sep;12(3):161-165. 10.14802/jmd.19029.
Recent Advances in the Development of Experimental Therapeutics for Levodopa-Induced Dyskinesia
- Affiliations
-
- 1Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA. michael.martini@icahn.mssm.edu
- 2Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- 3Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- 4James J. Peters VA Medical Center, Bronx, NY, USA.
- KMID: 2464633
- DOI: http://doi.org/10.14802/jmd.19029
Abstract
- No abstract available.
MeSH Terms
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Amantadine as Treatment for Levodopa-Induced Dyskinesia
- Less Pulsatile Levodopa Therapy (6 Doses Daily) Is Associated with a Reduced Incidence of Dyskinesia
- Levodopa-induced respiratory dysfunction in Parkinson’s disease managed with subthalamic nucleus deep brain stimulation
- Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
- Effect of Subthalamic Deep Brain Stimulation on Levodopa-Induced Dyskinesia in Parkinson's Disease
